These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 23689569

  • 1. Treatment of progressive IgA nephropathy: an update.
    Wang W, Chen N.
    Contrib Nephrol; 2013; 181():75-83. PubMed ID: 23689569
    [Abstract] [Full Text] [Related]

  • 2. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
    Eitner F, Ackermann D, Hilgers RD, Floege J.
    J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
    [Abstract] [Full Text] [Related]

  • 3. An update on the treatment of IgA nephropathy.
    Barbour S, Feehally J.
    Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):319-326. PubMed ID: 28399021
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Treatment of IgA nephropathy with chronic renal failure].
    Pozzi C.
    G Ital Nefrol; 2008 Jul; 25 Suppl 44():83-7. PubMed ID: 19048591
    [Abstract] [Full Text] [Related]

  • 7. Current therapy for IgA nephropathy.
    Floege J, Eitner F.
    J Am Soc Nephrol; 2011 Oct; 22(10):1785-94. PubMed ID: 21903997
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S, Li JP.
    Trials; 2020 Jan 06; 21(1):31. PubMed ID: 31907076
    [Abstract] [Full Text] [Related]

  • 11. [Management of IgA nephropathy].
    Amoroso L, De Sanctis L, Cappelli P, Di Vito R, Sirolli V, Bonomini M.
    G Ital Nefrol; 2011 Jan 06; 28(6):622-32. PubMed ID: 22167613
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of IgA nephropathy.
    Barratt J, Feehally J.
    Kidney Int; 2006 Jun 06; 69(11):1934-8. PubMed ID: 16641928
    [Abstract] [Full Text] [Related]

  • 15. Primary IgA nephropathy in elderly patients.
    Cheungpasitporn W, Nasr SH, Thongprayoon C, Mao MA, Qian Q.
    Nephrology (Carlton); 2015 Jun 06; 20(6):419-25. PubMed ID: 25726845
    [Abstract] [Full Text] [Related]

  • 16. Novel mechanisms of tubulointerstitial injury in IgA nephropathy: a new therapeutic paradigm in the prevention of progressive renal failure.
    Chan LY, Leung JC, Lai KN.
    Clin Exp Nephrol; 2004 Dec 06; 8(4):297-303. PubMed ID: 15619027
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.